-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Allogeneic Hematopoietic Stem Cell Transplant in ERCC6L2 Patients

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Program: Scientific Workshops
Session: How Scientific Advances Impact Clinical Predictive Models and Recommendations
Friday, December 8, 2023, 4:18 PM-4:59 PM

Urpu Salmenniemi

Dept of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

Disclosures: Salmenniemi: Astra Zeneca: Membership on an entity's Board of Directors or advisory committees; Immedia Pharma AB: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Viatris: Consultancy.

See more of: How Scientific Advances Impact Clinical Predictive Models and Recommendations
See more of: Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
See more of: Scientific Workshops
<< Previous Presentation | Next Presentation >>